Vit o cv2013
-
Upload
oliver-vit -
Category
Documents
-
view
542 -
download
0
description
Transcript of Vit o cv2013
Oliver Vit Lohnhofgaesslein 16 CH-4051 Basel Switzerland mobile: +41 79 346 38 40 [email protected]
Personal attributes Male Single Born 27th June 1972
Basel, Switzerland Polyvalent Analytical Persuasive Innovative Pragmatic Determined
Athletic Personal experience & achievements
New York3 yearsBachelor‘s degreeChemistry
New Jersey13 yearsCommunity CollegeHigh schoolEarly childhood
San Francisco7 yearsChildhood
Self sponsored, overland/sea travels
United KingdomPostgraduate diplomaStrategy & Innovation
Master of ScienceDrug DevelopmentHonors with distinction
Switzerland12 yearsActelion Pharmaceuticals LtdGlobal Business & Science AffairsSenior Life Cycle Project Manager
Citizenship
Switzerland Czech Republic
World Service USA Authority
Citizenship
Switzerland Czech Republic
World Service USA Authority
Education 2010 – 2011
2008 – 2009
1993 – 1996
University of Oxford Saïd Business School Postgraduate Diploma Strategy & Innovation University of London Queen Mary’s School of Medicine & Dentistry Master of Science in Drug Development Graduated with distinction New York University Bachelor’s Degree in Chemistry
Employment history Actelion Pharmaceuticals, Ltd Basel, Switzerland 2007 – 2012 Global Business & Science Affairs
Senior Life Cycle Project Manager In this position I authored protocols, developed target product profiles, co-authored clinical development plans, and conducted independent market research in parallel to grappling with moving targets and maintaining both team focus & morale. Working with no direct reports and within a matrix environment composed of members from almost every other internal department and potentially representatives of external partners, my professional function was to lead & support the Life Cycle Team as it drove programs forward through to the market respecting the limits set by the characteristics of each compound, the supporting fundamental sciences, the competitive environment, patent protection, the annual budget and Actelion's corporate vision. GB&SA was charged with the task of strategically linking apt, innovative research to both the needs of future prescribers and the continued growth of Actelion by bringing novel agents which address unmet medical needs robustly to the market in the timeliest manner. 2003 - 2006 Technical Operations
Clinical Trials Supplies Manager Upon joining Actelion, CTS management was a nascent competence and my remit extended well beyond negotiating cost efficient, timely packaging & delivery of QP released supplies globally in support of Actelion's growing number of clinical trials. In addition to liaising between the clinical teams and the 3rd party providers, I was charged with multiple tasks in building the CTS unit, e.g. writing the first SOPs, establishing global distribution networks, creating & implementing the first interdepartmental software which was used to monitor CTS stocks globally, initiate, track & trace shipments and record compliant returns & destruction prior to study closure. I was also responsible for the recruitment and training of new employees who eventually replaced the previous team under my guidance.
Almedica HPS AG Reinach, Switzerland 2001 - 2003 Client Services
Global Project Manager As my first professional experience in Switzerland this position made use of my ability to speak multiple languages, consult, pitch & negotiate contracts with potential clients in the pharmaceutical industry, identify & satisfy customer needs, understand & coordinate internally across all departments & functions to ensure both GMP compliance and the timely internal release of packaged materials within budget, and liaise with both the US head office and UK affiliate.
Products & candidates
In my role as a Senior Life Cycle Project Manager I led the multi-disciplined life cycle teams for cadazolid, olesoxime and the ponesimod follow-up compound while having provided assistance to the life cycle teams charged with the development of ponesimod, an anti-hypertensive and Zavesca® (miglustat). This cross-functional leadership role encompasses: setting & adhering to the annual budget, drafting, finalizing & adapting the integrated project plans, execution of development strategy, identification of development hurdles & market opportunities, generation, review & updating of most critical core documentation, setting & achieving project goals, matrix management, challenge & defense of corporate strategy. I have worked with multiple drug candidates & marketed products from a wide array of molecular targets employing different formulations across numerous indications in development stages: Phase I, II, III, and IV. In particular both the olesoxime and ponesimod projects were managed while in partnerships with both Trophos SA and Hoffmann-La Roche Ltd respectively.
CompoundClass
Mode of action Route ofadministration
Indication
Anti-hypertensive
L/T channel blocker oral capsule HypertensionAngina pectoris
Cadazolid Inhibition of topoisomerase & protein synthesis
oral suspension Clostridium difficile infection
Ponesimod
Sequestration of T-cells in lymph nodes and Peyer‘spatches
oral tablet
Multiple sclerosisPlaque psoriasisOther
Ponesimod f/u Auto-immune disorders
Olesoxime Mitochondrial permeability transition pore modulation
oral liquid filled capsugel
Amyotrophic Lateral SclerosisSpinal muscular atrophy
Zavesca® (miglustat)
Inhibition of glucosylceramidesynthase
oral capsule Type I GaucherNiemann-Pick Type C
Recent professional experience & group achievements
Protocols * Investigator’s brochures * Clinical development plans * Target product profiles * Competitive intelligence briefings * Business case development Alliance management Risk management plans Expert panel meetings Annual budgets New indication research * INN filings Patent filings
Pre-IND meetings o Neurology division o Dermatology division o Division of special
pathogens & transplant Clinical Trial Applications
o EU/EEA o Israel
IND filings o Neurology division o Division of special
pathogens & transplant *authorship
DISCOVERYDEVELOPMENT
MARKETING
Target selectionHTS
Lead optimisation
Candidate selection process
Preclinical testing
Safety testing Phase I
Concept testing Phase II
Full scale developmentPhase III
Submission
LaunchCommercialisation
• ••
• ••
Entry into Human
First dose inindication
First submissionFirst approval
LeadHit
• Launch key markets
Anti-hypertensive
Cadazolid
Ponesimod
Ponesimod f/u
Olesoxime
Zavesca®
Corporate deliverables inclusive of academic theses (sample non-confidential files available upon request) 2011 Actelion Pharmaceuticals Ltd Proof-of-concept protocols Target product profiles Investigator’s brochure Saϊd Business School, Oxford University Postgraduate Diploma in Strategy & Innovation “Actelion Pharmaceuticals Ltd, the Quest for a 2nd Partner” 2010 Actelion Pharmaceuticals Ltd Competitive intelligence reports Crohn’s Disease, Pharmascape Psoriasis, Pharmascape 2009 Queen Mary’s School of Medicine & Dentistry, University of London Master of Science in Drug Development “Oral MS Therapy, the Coming Revolution” Actelion Pharmaceuticals Ltd Multiple Sclerosis, Clinical Development Plan
FINAL 2011 DipSI Thesis Oliver Vit CV.pdf
Crohn's Disease Pharmascape CV.pdf
Psoriasis Pharmascape CV.pdf
FINAL 2009 MSc Thesis Oliver Vit CV.pdf
Languages
Recent conferences & trainings 2011 2010 2009
Imperial College London Immunology for Physicians & Clinicians European Committee for Treatment & Research in Multiple Sclerosis (ECTRIMS) International Society for Pharmacoeconomics & Outcomes Research (ISPOR) 12th annual conference
SpanishPortuguese
GermanFrench
English
Rudimentary
Conversational&
Written
Fluent
SpanishPortuguese
GermanFrench
English
Rudimentary
Conversational&
Written
Fluent
References Actelion Pharmaceuticals Ltd Novartis Pharma AG Bayer HealthCare Pharmaceuticals Stanford University University of London Queen Mary’s School of Medicine & Dentistry William Harvey Institute Clinical Pharmacology
Isaac Kobrin, MD (retired) Senior Vice President Chief Medical Officer [email protected] +41 79 372 68 66 Michael Scherz, PhD Vice President Life Cycle Leader [email protected] +41 61 565 65 94 Jasper Dingemanse, PhD Vice President Head of Clinical Pharmacology [email protected] +41 61 565 64 63 Vaclav Sulista, PhD PU Head TRD Services [email protected] +41 61 696 13 21 Malcolm Allison Vice President Global Team Leader PH [email protected] +49 175 309 27 50 Jed Black, MD Consulting professor Actelion Vice President (former) Therapeutic Area Head Sleep Disorders [email protected] +1 650 464-9129 (GMT-8 h) Atholl Johnston, PhD Professor of Clinical Pharmacology Head of Postgraduate Taught Courses [email protected] +44 20 7882 3404
Current attestation
Additional attestations
Diplomas